<DOC>
	<DOCNO>NCT01846949</DOCNO>
	<brief_summary>This study intend prospective observational study multiple site , randomize control trial ( RCT ) . The uses biomarkers approve government regulation adopt surveillance program country , thus RCT compare patient follow US alone patient follow US biomarkers would raise ethical conflict , especially country biomarkers routinely use . For study , enrol patient follow US biomarkers regular interval classify complete study evaluate clinical effectiveness biomarkers . The comparison sensitivity , specificity , parameter respect tumor characteristic make among US alone , biomarkers , combine use US biomarkers . Also economical effectiveness use biomarkers investigate study .</brief_summary>
	<brief_title>Surveillance Study HCC ( ALDUS )</brief_title>
	<detailed_description />
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Patients compensate cirrhosis . No discrimination underlie cause do . Patients age 18 year old Patients agree informed consent Patients liver cancer time enrollment Patients experience HCC malignant tumor five ( 5 ) year Women pregnancies Patients likely transplant within one ( 1 ) year Patients ≥ 3 mg/dL total bilirubin Patients uncontrollable ascites Patients ≥ Grade II hepatic encephalopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>